Background We used the RNActive® technology platform (CureVac NV, Tübingen, Germany)
to prepare CVnCoV, a COVID-19 vaccine containing sequence-optimized mRNA coding …

There is an urgent need for vaccines to counter the COVID-19 pandemic due to infections
with severe acute respiratory syndrome coronavirus (SARS-CoV-2). Evidence from …

Background The Nod-like receptor NACHT, LRR, and PYD domain–containing protein 3 (NLRP3)
and Bruton tyrosine kinase (BTK) are protagonists in innate and adaptive immunity, …

The adaptor protein MYD88 is critical for relaying activation of Toll-like receptor signaling to
NF-κB activation. MYD88 mutations, particularly the p.L265P mutation, have been described …

Chitin is the second most abundant polysaccharide in nature and linked to fungal infection
and asthma. However, bona fide immune receptors directly binding chitin and signaling …

Myeloid differentiation 88 (MyD88) is the key signaling adapter of Toll-like and interleukin-1
receptors. Recurrent lymphoma-associated mutations, particularly Leu265Pro (L265P), …

Activity of the NLRP3 inflammasome, a critical mediator of inflammation, is controlled by
accessory proteins, posttranslational modifications, cellular localization, and oligomerization. …

Oncogenic MYD88 mutations, most notably the Leu 265 Pro (L265P) mutation, were
recently identified as potential driver mutations in various B-cell non-Hodgkin Lymphomas (NHLs). …

Activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL) is an aggressive lymphoproliferative
disorder involving chronic NF-κB activation. Several mutations in the BCR and MyD88 …

Genome sequencing has uncovered an array of recurring somatic mutations in different non-Hodgkin
lymphoma (NHL) subtypes. If affecting protein-coding regions, such mutations may …